Compare Grab Holdings Ltd. (GRAB) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Grab Holdings Ltd. vs GSK plc — how do they compare? Grab Holdings Ltd. trades at $3.19 (market cap $12.72B), while GSK plc trades at $46.5 (market cap $91.88B). The key difference: GSK plc is far larger — about 7.2× Grab Holdings Ltd.'s market cap, and GSK plc pays a 3.9% dividend while Grab Holdings Ltd. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Grab Holdings Ltd. for 94 Days and GSK plc for 93 Days on average.
| GRAB | GSK | |
|---|---|---|
Market Cap | $12.72B | $91.88B |
Volume | 65,352,859 | 7,730,529 |
Sector | Technology | Health |
52-Week High | $6.12 | $61.18 |
52-Week Low | $2.80 | $43.24 |
Typical Hold Time | 94 Days | 93 Days |
Enterprise Value | $8.46B | $111.88B |
Dividend Yield | — | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GRAB Holdings trades at $3.11, up 0.97% with a bearish technical signal despite recent earnings beats. The company achieved profitability in 2025 with $268M net income and maintains strong analyst support (91.67% buy ratings). Recent developments include a $1.49B acquisition of Atome Financial and $30M in insider buying, though the stock faces headwinds from regional protests and competitive pressures.
GRAB's transition to profitability and Southeast Asian expansion present growth opportunities, but investors face risks from aggressive capital deployment, regulatory challenges, and volatile cash flow patterns. The stock's current valuation metrics (P/E 28.27, P/S 3.81) reflect optimism about future earnings potential despite near-term technical weakness.
GSK trades at $46.54, down 1.02% with bearish technical signals but strong fundamentals including 29.73% ROE and consistent earnings beats. The company maintains robust profitability with 72.73% gross margins and is actively expanding its oncology pipeline through strategic partnerships. Recent developments include a $750M cancer therapy acquisition and advancing mRNA vaccine candidates.
GSK presents a mixed outlook with strong operational performance offset by technical weakness. Investment appeal lies in valuation multiples below industry averages and pipeline expansion, though risks include HIV patent expirations and manufacturing restructuring. Analyst consensus leans cautious with 55% hold ratings amid near-term headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Grab Holdings Ltd.
Grab Holdings Limited operates as a holding company. The Company, through its subsidiaries, develops delivery management, mobility, financial services, and enterprise software solutions. Grab Holdings serves customers worldwide.
Read more on GRAB →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
